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Abstract: Elastic fiber fragmentation (EFF) is a hallmark of aortic valve disease (AVD), and neovascularization has been identified as a late finding related to inflammation. We sought to characterize the
relationship between early EFF and aberrant angiogenesis. To examine disease progression, regional
anatomy and pathology of aortic valve tissue were assessed using histochemistry, immunohistochemistry, and electron microscopy from early-onset (<40 yo) and late-onset (≥40 yo) non-syndromic
AVD specimens. To assess the effects of EFF on early AVD processes, valve tissue from Williams and
Marfan syndrome patients was also analyzed. Bicuspid aortic valve was more common in early-onset
AVD, and cardiovascular comorbidities were more common in late-onset AVD. Early-onset AVD
specimens demonstrated angiogenesis without inflammation or atherosclerosis. A distinct pattern
of elastic fiber components surrounded early-onset AVD neovessels, including increased emilin-1
and decreased fibulin-5. Different types of EFF were present in Williams syndrome (WS) and Marfan
syndrome (MFS) aortic valves; WS but not MFS aortic valves demonstrated angiogenesis. Aberrant
angiogenesis occurs in early-onset AVD in the absence of inflammation, implicating EFF. Elucidation
of underlying mechanisms may inform the development of new pharmacologic treatments.
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1. Introduction
Aortic valve disease (AVD) obstructs outflow from the heart, affects 2.5% of the general
population, and remains a significant cause of mortality [1,2]. Genetic and environmental
risk factors have been identified. The treatment for AVD continues to be primarily surgical,
restricted to late-stage disease, and the number of replacement procedures increases rapidly
with the aging population [3,4]. A central problem in the field remains the need to better
understand early AVD processes and alternative medical treatment strategies [5]. AVD
is characterized by cell and matrix abnormalities that are well established. Advances in
human genetics and developmental biology have elucidated mechanisms that contribute
to pathogenesis [6,7], but to date, early disease processes remain poorly understood, and
no pharmacologic-based treatments that directly treat AVD have been established.
Aberrant angiogenesis was originally described in cancer literature, and since then, a
fundamental role for this biologic process has been established in other disease states that
affect typically avascular tissue [8,9]. Aberrant angiogenesis has been described in nonrheumatic AVD [10–13] and is widely interpreted to represent a secondary finding of inflam-
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mation, typically due to atherosclerosis [14,15]. However, children without atherosclerosis
develop AVD, and the potential use of 3-Hydroxy-3-Methylglutaryl coenzyme-A reductase
inhibitors (statins), an effective therapy for atherosclerosis, to treat AVD has shown no
effect on the progression of AVD or the need for aortic valve replacement [16]. The potential
role of aberrant angiogenesis in early-onset AVD pathogenesis is unknown.
Elastic fiber abnormalities have long been identified as a central finding of AVD,
including markedly diminished elastic fibers that are fragmented and dispersed throughout the valve cusp layers [17–19]. AVD in pediatric patients is characterized by similar
extracellular matrix (ECM) disorganization, including elastic fiber fragmentation (EFF), but
without inflammation or calcification [20,21]. Both Williams (OMIM#194050) and Marfan
(OMIM#154700) syndromes, associated with mutations in the elastic fiber genes elastin
(ELN) and fibrillin-1 (FBN1), respectively, are associated with valve malformation and disease in 20–45% of cases [22,23]. The histopathology abnormalities of valves in these genetic
syndromes are distinct, but each overlap with non-syndromic AVD [23,24]. Interestingly,
it has been shown that intact elastic fibers are angiostatic, and elastic fiber fragments are
angiogenic [25,26], consistent with a potential role for EFF in the manifestation of neovascularization in AVD; however, the relationship between EFF and aberrant angiogenesis in
the context of AVD is unknown.
The anatomy of the mature aortic valve is complex. There are normally three semilunar
cusps hinged to a crown-shaped collagenous annulus within the aortic root [27,28]. The
cusp extracellular matrix (ECM) organization is trilaminar (fibrosa, spongiosa, ventricularis)
with elastic fibers radially organized as filaments in the ventricularis layer [29]. Elastic
fibers consist of multiple components, including elastin, fibrillin-1, emilin, and fibulins that
are coordinately expressed throughout the valve and spatio-temporally regulated during
embryogenesis to facilitate fiber assembly in the ventricularis [30,31]. The ring spongiosa
is a subsection of the spongiosa layer located at the interface between the annulus and
cusp that functions as the hinge of the valve and consists of proteoglycans and elastic
fiber components [29,32]. Little is known about the potential role of the annulus and ring
spongiosa regions in AVD.
The objective of this study was to examine the impact of EFF in AVD progression. We
hypothesized that early AVD would be characterized by angiogenesis, which is associated
with EFF. Our findings identified EFF and aberrant angiogenesis in early-onset AVD, establishing the role of elastic fiber dysregulation in AVD pathogenesis preceding inflammation.
These studies advance our understanding of early disease processes, potentially facilitating
the identification of new pharmacologic treatments.
2. Materials and Methods
2.1. Human Valve Tissue
Aortic valve specimens were obtained from non-syndromic patients with isolated AVD
undergoing aortic valve replacement (affected), and from age-matched individuals who
died of non-cardiac causes (control) at the time of autopsy. AVD patients were stratified
by age into early-onset (0–40 yo) and late-onset (41–85 yo) groups. Patients with a history
of rheumatic heart disease or infective endocarditis were excluded. Medical records were
reviewed, and aortic valve morphology and major cardiovascular comorbidities were
noted, including coronary artery disease (CAD), essential systemic hypertension (HTN),
diabetes mellitus (DM), thoracic aortic aneurysm (TAA), and chronic kidney disease (CKD).
These studies were approved by the Institutional Review Boards at Cincinnati Children’s Hospital Medical Center (CCHMC) and Good Samaritan Hospital (Cincinnati, Ohio).
In addition, human heart specimens were obtained from pediatric patients with either
Williams or Marfan syndrome from the Cardiac Registry at Children’s Hospital Boston;
these studies were approved by the Institutional Committee on Clinical Investigations.
For comparison purposes, whole heart specimens from age-matched patients with nonsyndromic isolated AVD (affected) and non-cardiac disease (control) were obtained from
the Teaching Collection at CCHMC.
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2.2. Histochemistry
Valve tissue was processed and analyzed as previously described [20]. Movat’s modified pentachrome stain was used to examine ECM organization and alizarin red to assess
calcification. Whole hearts were dissected precisely to demonstrate the aortic sinus equidistant from the adjacent commissures and the aortic valve annulus at its most proximal
position. Comprehensive morphometrics were obtained in comparable sections, including
tissue thickness dimensions for the ascending aorta, sinotubular junction, aortic root, and
valve (hinge, proximal, distal), as well as area measurements for the annulus and ring
spongiosa regions.
2.3. Immunohistochemistry
Antibodies directed against elastic fiber components, as well as markers of angiogenesis, inflammation, and atherosclerosis, were examined (Supplemental Material, Table
S1). A universal streptavidin/biotin and diaminobenzidine detection system (Vector) was
used for colorimetric detection, as previously described [20,21]. High heat sodium citrate
antigen retrieval was used for pretreatment of all antibodies except elastin, which used
enzymatic trypsin pretreatment. Angiogenesis was considered present if there was VEGF
immunoreactivity without neovessel formation (provisional) or with neovessel formation
(overt) [33]. Due to AVD tissue heterogeneity, a semi-quantitative assessment of VEGF
and CD-68 expression was performed using a scale described by Alexopoulous et al. [34].
Briefly, staining was graded on a scale from 0 to 3 based on the percentage of positive cells
as follows: 0–immunoreactivity in <10% of cells, 1—10–35%, 2—35–70%, and 3—>70%.
2.4. Transmission Electron Microscopy
Valve tissue ultrastructure was examined (Hitachi 7600, Hitachi, Shaumberg, IL, USA)
on epoxy resin sections from 10% NBF fixed control, WS, and MFS specimens [20]. For
visualization of collagens and elastins, sections were stained with 5% tannic acid aqueous
solution, followed by 1% uranyl acetate, and counterstained with lead citrate.
2.5. Statistical Analysis
Student’s t-test or one-way ANOVA was used to compare groups. Findings are reported as the mean ± SEM. A p < 0.05 was considered significant.
3. Results
3.1. Study Population
Non-syndromic patients with AVD were stratified by age. Early-onset AVD specimens
were obtained from patients aged 1 to 32 years (n = 21) and were compared with lateonset AVD specimens obtained from patients aged 44 to 85 years (n = 11). Both disease
groups were also compared with age-matched controls (n = 8 each) that did not have AVD.
The indication for surgery in all cases was stenosis, although some had mixed disease
(stenosis and insufficiency). Bicuspid aortic valve (BAV) was more common in earlyonset AVD, whereas cardiovascular comorbidities were more common in late-onset AVD
(Table 1), consistent with previous findings [21,35,36]. Importantly, clinically significant
atherosclerosis (CAD) was not present in any early-onset AVD case.
Aortic valve specimens from syndromic patients were obtained from WS (n = 6, mean
age 22 months), MFS (n = 4, mean age 10 months), and compared with pediatric AVD
(n = 3, mean age 12 months), and control (n = 3, mean age 5 months) patients. In addition
to the characteristic arteriopathy (supravalvar aortic stenosis, SVAS) or aortopathy (dilated
aortic root) identified in all WS and MFS cases examined, respectively, clinical evidence of
AVD was documented in three out of five (one unknown) WS patients (one with BAV) and
two out of four MFS patients (none with BAV).
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Table 1. Non-syndromic AVD study population demographics and comorbidities.
Early-Onset AVD

Late-Onset AVD

p

N

21

11

-

Mean Age (Range)

15 (1, 32)

67 (44, 85)

-

Male (%)

81

73

NS

BAV (%)

48

27

0.08

CAD (%)

0

45

<0.003

HT (%)

10

55

<0.002

TAA (%)

10

18

NS

DM (%)

5

36

0.08

CKD (%)

0

9

<0.001

AVD, aortic valve disease; BAV, bicuspid aortic valve; CAD, coronary artery disease; CKD, chronic kidney disease;
DM, diabetes mellitus; HT, systemic hypertension; NS, not significant; TAA, thoracic aortic aneurysm.

3.2. Early-Onset AVD Specimens Demonstrate Aberrant Angiogenesis without Inflammation
or Atherosclerosis
Overt angiogenesis was present in 11/11 (100%) late-onset and 8/21 (38%) earlyonset AVD specimens. Among the early-onset AVD subgroup, 16/21 were from pediatric
patients (≤18 years old), and 4/16 (25%) showed overt angiogenesis. In both groups,
neovessels were identified in all cusp layers and the annulus with an increased proportion
of vessels recognized in the proximal aspect of the cusp, including the ring spongiosa;
however, vessels in early-onset AVD specimens were fewer in number and smaller in
diameter. Provisional angiogenesis was present to the same extent in all early- and lateonset AVD specimens but was not detected in age-matched controls. VEGF expression is
increased in the interstitium heterogeneously in both early and late-onset AVD (Figure 1).
CD-31 identified endothelial cells associated with neovessels but only scant interstitial
cells, suggesting most VEGF-positive cells are not endothelial in origin. CD-31 positive
neovessels were quantified and stratified as microvessels or arterioles (Table 2).
Table 2. CD-31 neovessel quantification and stratification.
Microvessels

Arterioles

Total (Vessels/10×)

Control

0

0

0

Early AVD

0.7

0.2

0.9

Late AVD

3.7

1.9

5.6

Chondromodulin, an angiostatic factor, is decreased in all AVD specimens, as previously described [10]. Importantly, the inflammation marker CD-68 is strongly expressed in
VIC clusters spatially associated with calcific nodules in late-onset AVD but are virtually
absent from the majority of early-onset specimens, similar to controls, suggesting upregulation of VEGF arose from resident cell populations. Semi-quantitative analysis for VEGF
and CD-68 is reported in Table 3. Similarly, the Wnt/beta-catenin signaling marker LRP-5,
which has been used to identify atherosclerosis, is absent from early-onset AVD and control
specimens but is strongly expressed in late-onset AVD, as previously described [14]. Provisional and overt angiogenesis occur in early-onset AVD without clinical or histopathologic
evidence of inflammation or atherosclerosis.
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Chondromodulin, an angiostatic factor, is decreased in all AVD specimens, as previously described [10]. Importantly, the inflammation marker CD-68 is strongly expressed
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Table 3. VIC relative expression of angiogenesis and inflammation.
VEGF-A

CD-68

Score

Control

Early AVD

Late AVD

Control

Early AVD

Late AVD

0 (0–10% + cells)
1 (10–35% + cells)
2 (35–70% + cells)
3 (>70% + cells)

100%
0%
0%
0%

0%
21%
57%
21%

18%
27%
36%
18%

100%
0%
0%
0%

73%
18%
9%
0%

20%
40%
40%
0%

Mean (SD)

0±0

2.0 ± 0.7 *

1.6 ± 1.0 *

0±0

0.4 ± 0.7

1.3 ± 0.8 *,#

* p < 0.05 vs. Control; # p < 0.05 vs. Early AVD.

3.3. A Distinct Pattern of Elastic Fiber Components Is Associated with Early-Onset
AVD Neovessels
In early-onset AVD, elastic fibers are decreased, fragmented, and dispersed in general,
as previously reported in late-onset AVD [17]; however, the distribution of specific elastic
fiber components is distinct (Figure 2). Elastin is present in the fragments surrounding
neovessels, whereas fibrillin is present in the lining of the neovessels but not in the area
around them. Emilin, an elastic fiber glycoprotein that binds tropoelastin to the microfibril,
is increased in all layers and present predominantly in the area surrounding neovessels.
Fibulin-4, but not fibulin-5, is present around neovessels. Finally, LOX expression, normally
present throughout the valve but preferentially in the ventricularis layer, was not changed
in AVD specimens compared with controls and was not associated with neovessels. These
patterns were similar in early and late-onset AVD groups. Of note, some EFF was associated
with both neovessels and calcific nodules in late-onset AVD (data not shown) [37,38].
Therefore, differential expression of elastic fiber components is associated with aberrant
angiogenesis in early-onset AVD.
3.4. WS but Not MFS Aortic Valves Demonstrate Aberrant Angiogenesis
To better understand the role of EFF in AVD pathogenesis, we examined the aortic
valves from WS and MFS patients and compared them with early-onset AVD specimens
(Figure 3). All syndromic specimens examined had histopathologic evidence of AVD.
Paradoxically, elastic fiber content was markedly increased in the ventricularis layer of both
WS and MFS specimens compared with non-syndromic AVD, but patterns of elastic fiber
disorganization and fragmentation were different. Aortic valves from WS patients show
more intra-EFF (within a bundle) and dispersion, while aortic valves from MFS patients
show more inter-EFF (between bundles) and delamination. Interestingly, WS aortic valves
demonstrate angiogenesis, but MFS valves do not. Elastic fiber fragments in WS were
dispersed, whereas in MFS they were restricted to the ventricularis layer. In early-onset
AVD, there is EFF characterized by inter- and intra-fiber fragmentation, dispersion of the
fragments to all layers of the valve as well as the annulus and thinning of fibers that often
remain intact with delamination. Therefore, different patterns of EFF are observed in WS
and MFS aortic valves; each share characteristics seen in early-onset AVD .
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Figure 2. Specific elastic fiber components are associated with overt angiogenesis. Representative

Figure 2. Specific elastic fiber components are associated with overt angiogenesis. Representative
sections from control (left column, A,C,E,G,I,K) and early-onset AVD (right column, B,D,F,H,J,L)
sections from control (left column, A,C,E,G,I,K) and early-onset AVD (right column, B,D,F,H,J,L)
specimens. In control tissue, elastin and fibulin-5 are localized in the cusp ventricularis layer (arspecimens. In control tissue, elastin and fibulin-5 are localized in the cusp ventricularis layer (arrows),
rows), but fibrillin, emilin, fibulin-4, and LOX are also expressed weakly in all layers (arrowheads).
but fibrillin, emilin, fibulin-4, and LOX are also expressed weakly in all layers (arrowheads). In
In AVD tissue, elastin, fibrillin, emilin, and fibulin-4 are associated with neovessels (asterisk,
AVD
tissue, elastin,
emilin,
and fibulin-4
are associated with neovessels (asterisk, B,D,F,H),
B,D,F,H),
whereasfibrillin,
fibulin-5
and LOX
are not (J,L).
whereas fibulin-5 and LOX are not (J,L).
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demonstrate angiogenesis, but MFS valves do not. Elastic fiber fragments in WS were dispersed, whereas in MFS they were restricted to the ventricularis layer. In early-onset AVD,
there is EFF characterized by inter- and intra-fiber fragmentation, dispersion of the fragments to all layers of the valve as well as the annulus and thinning of fibers that
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remain intact with delamination. Therefore, different patterns of EFF are observed in WS
and MFS aortic valves; each share characteristics seen in early-onset AVD.

Figure 3. Elastic fiber dysregulation impacts regional aortic valve structure. Regional aortic valve
Figure 3. Elastic fiber dysregulation impacts regional aortic valve structure. Regional aortic valve
tissue (annulus, ring spongiosa, cusp) from control (A), early-onset AVD (B), WS (C), and MFS (D)
tissue (annulus, ring spongiosa, cusp) from control (A), early-onset AVD (B), WS (C), and MFS (D)
specimens demonstrate specific differences in matrix organization. EFF in WS and MFS is different
specimens demonstrate specific differences in matrix organization. EFF in WS and MFS is different
(arrows, C vs. D). Neovessels are seen in WS (arrowhead, C) but not MFS.
(arrows, C vs. D). Neovessels are seen in WS (arrowhead, C) but not MFS.

3.5. The Aortic Root Is Composed in Part of Valve Tissue
Comprehensive morphometrics demonstrated increased valve and aorta thickness
in WS specimens (Supplemental Material, Figure S1). Neither WS nor MFS aortic valves
demonstrated calcification (data not shown). Neovessel formation in both WS and AVD
whole heart specimens was localized to the proximal third of the cusp, the ring spongiosa,
and to a limited degree the annulus, where EFF was concentrated. In WS patients, in
addition to substantial collagen accumulation in the sinotubular junction (STJ), fibrillin and
emilin were present within the fibrous aspect of the STJ (Supplemental Material, Figure S2).
Neovessels were identified both in the fibrous STJ and the intimal aspect of the aortic media
in WS. Conversely, the STJ in MFS was completely effaced, demonstrating loss of normal
landmarks and no fibrous tissue. The aortic root demonstrated markedly more severe
disease compared with the ascending aorta in all groups, but the patterns of histopathology
were distinct by group (Supplemental Material, Figure S3). In addition to established
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findings [39], the WS specimens demonstrated more inter-EFF, whereas the MFS specimens
demonstrated more intra-EFF. In AVD, there was less pronounced aortopathy in both the
root and ascending aorta, which manifested localized areas of both inter- and intra-EFF
with modest proteoglycan accumulation. Elastic fiber dysregulation contributes to both
AVD and aortopathy, consistent with the clinical association, but there are different patterns
of EFF by tissue type.
3.6. Different Elastic Fiber Defects Result in Different Types of EFF
An ultrastructural analysis of the aortic valve annulus and cusp regions in WS and
MFS identified distinct elastic fiber abnormalities (Figure 4). In control specimens, elastic
fiber components were present in the cusp ventricularis layer organized as filaments
and the ring spongiosa in an unorganized fashion but were not present in the annulus.
WS specimens demonstrated predominantly intra-EFF in the cusp and EFF dispersion
throughout the valve, including in the annulus region, consistent with the histochemistry
described above. MFS specimens demonstrated primarily inter-EFF in the cusp and EFF
dispersion into the annulus but not the rest of the cusp. The elastin is characterized
by a “moth-eaten” edge and a decrease in surface microfibrils, consistent with classic
descriptions of fibrillin in MFS [40]. Proteoglycans were present in the annulus region
of WS specimens, but not MFS or controls. Collagen fibers were disorganized in both
WS and MFS groups by region compared with control specimens and previous regional
descriptions [32,41]. Specifically, in WS, the collagen fiber diameters were irregular and
small in the cusp region only, but in MFS, the collagen fiber diameters were irregular
andREVIEW
small in the annulus region. Ultrastructure analysis demonstrated a spectrum10of
J. Cardiovasc. Dev. Dis. 2021, 8, x FOR PEER
of 16
overlapping but with subtly distinct types of EFF in regional syndromic valve tissue,
consistent with elastase-mediated degeneration.
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4. Discussion
The findings of this study identify EFF and aberrant angiogenesis as early disease
processes underlying AVD preceding the manifestation of inflammation (Figure 5). These
results establish a central role for elastic fiber dysregulation in early AVD pathogenesis,
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4. Discussion
The findings of this study identify EFF and aberrant angiogenesis as early disease
processes underlying AVD preceding the manifestation of inflammation (Figure 5). These
results establish a central role for elastic fiber dysregulation in early AVD pathogenesis,
suggesting that faulty elastic fiber assembly and consequent elastase-mediated tissue injury
contribute to disease initiation and progression. The demonstration of different types of EFF
in WS and MFS aortic valves suggests that specific elastic fiber components may function
in distinct ways resulting in a spectrum of disease processes. Finally, these data suggest
that the annulus and ring spongiosa regions, where both shear and oscillatory stresses are
concentrated and EFF and angiogenesis occur, are important in the manifestation of AVD.
EFF and aberrant angiogenesis represent two disease processes that may be identifiable
and modifiable early in the clinical course of AVD.
The prevailing view is that AVD is an inflammatory process, commonly associated
with atherosclerosis, similar to wound healing response. In this context, tissue injury leads
to inflammation and myofibroblast activation, which in turn leads to fibrosis and neovascularization [42]. Findings from previous studies support an inflammatory mechanism in
the context of end-stage AVD [11,15], but it is unclear whether this represents the inciting
pathology or a secondary factor that accelerates AVD progression [43,44]. Increasing evidence suggests additional mechanisms contribute to early AVD pathogenesis, including
dysregulation of developmental programs [7,45–49], which may predispose valve tissue
to inflammation. A strength of this current study is the strategy to compare early with
late-onset AVD specimens [20,21] to control for the confounding effects of common comorbidities associated with inflammation in adulthood, including aging [50]. Here we have
J. Cardiovasc. Dev. Dis. 2021, 8, x FOR PEER REVIEW
11 of 16
shown for the first time that EFF and aberrant angiogenesis occur in early-onset AVD in
the absence of inflammation in valve tissue.
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others are chemo-attractants for endothelial cells [56,57]. Consistent with this idea, we
have demonstrated aberrant angiogenesis in WS but not MFS aortic valves, suggesting
elucidation of different elastic fiber fragment functions may identify new mechanisms underlying early AVD [58].
Gross and Kugel described the anatomy of mature heart valves in detail, noting the
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have demonstrated aberrant angiogenesis in WS but not MFS aortic valves, suggesting
elucidation of different elastic fiber fragment functions may identify new mechanisms
underlying early AVD [58].
Gross and Kugel described the anatomy of mature heart valves in detail, noting the
presence of elastic fiber components in the annulus, ring spongiosa, and fibrosa, in addition
to organized elastic fiber filaments in the ventricularis [29]. In the present study, EFF and
angiogenesis were demonstrated predominantly in the ring spongiosa and proximal aspect
of the cusp, supporting previous observations suggesting that disease begins and worsens
in the hinge area [32,43,59]. The annulus and ring spongiosa regions are especially prone to
degeneration due to secondary insults, such as shear and compressive stresses [60–62]. Woo
et al. elegantly demonstrated a complex interaction between developmental programs that
predispose tissue to disease and shear stresses that trigger inflammation [63], providing
an example of how these factors together contribute to AVD. Elastic fiber lamellae, the
circumferential organizational unit of the ascending aorta, are disrupted in the aortic root
by valve tissue due to the valve annulus’s irregular crown shape, which extends distally to
the STJ. Interestingly, we observed a discrete string of cartilage-like halo cells separating
the fibrous valve annulus tissue from the aortic media in the STJ (the site of obstruction in
SVAS), similar in composition and location to cartilage nodules seen in the valve annulus
of the elastin haploinsufficient mouse model of AVD [64,65]. The STJ in WS patients is
characterized by fibrous overgrowth, in addition to dramatic thickening of the aortic media,
suggesting that the left ventricular outflow tract obstruction seen in SVAS is due in part to
valve disease processes. These results suggest that focused examination of the annulus and
ring spongiosa regions in both human and animal research will inform our understanding
of AVD progression.
Both early and late-onset AVD is characterized by EFF. Our findings suggest that some
elastic fiber fragments, or specific types of EFF, result in aberrant angiogenesis, underscoring the importance of delineating elastic fiber development [66]. Since our understanding
of human AVD pathogenesis is limited to observations in late-stage disease, animal models
are necessary to identify mechanisms that contribute to early pathogenesis. Targeted mutagenesis of elastic fiber genes in mice has generated models characterized in part by valve
phenotypes, including elastin, emilin-1, fibrillin-1, and fibulin-4 [64,67–69]. Likewise, genes
that regulate angiogenesis, including VEGF, chondromodulin, and periostin, also play a
role in valve development and disease [70–72]. The emilin-1 mutant mouse model of AVD
demonstrates both EFF and aberrant angiogenesis [67], but the elastin haploinsufficent
mouse model of AVD does not [64]. Other elastic fiber mouse models have been associated
with pro-angiogenic effects or vasculature defects, but they have not reported on the potential presence of neovessels in valve tissue [55]. EFF and angiogenesis represent two early
disease processes that may lead to new pharmacologic-based treatment strategies.
Presently, there are no pharmacologic-based treatment strategies for AVD. Clinical
studies have identified risk factors for AVD progression, but studies examining human
AVD tissue are restricted to late-stage disease. As a result, our understanding of early pathogenesis is limited. The observation that EFF and angiogenesis are early disease processes
suggests that elastase and angiogenesis inhibitors represent potential new pharmacologic
treatments for AVD that prevent disease progression and the need for surgery [8,73]. While
nonspecific clinical risk factors for AVD have been established [36], predictive biomarkers
have not been identified for early AVD progression. Aortic valve sclerosis, or thickening of
the aortic valve, is a late marker of cardiovascular risk but not a specific marker for AVD [74].
The systemic effects of EFF and aberrant angiogenesis in valve tissue may provide these
specific biomarkers, such as an increase in specific types of urine elastin degradation products. Finally, a better understanding of EFF-induced cell-matrix perturbations may inform
the search for durable valve bioprostheses [75].

J. Cardiovasc. Dev. Dis. 2021, 8, 75

12 of 15

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/jcdd8070075/s1, Table S1: Specifications of primary antibodies, Figure S1: Regional aortic valve
and aorta pathology in syndromic and non-syndromic AVD, Figure S2: Valve tissue contributes to the
sinotubular junction (STJ) narrowing in the WS aorta (AO), and Figure S3: Aortic root histopathology
is more severe and distinct from ascending aorta pathology in syndromic and nonsyndromic AVD.
Author Contributions: Conceptualization of the work, R.B.H.; methodology and investigation,
R.B.H., A.L.J., A.M.O., J.M.S. and K.E.B.; analysis, R.B.H., A.L.J., A.M.O., B.J.L., J.M.S., R.P.M.
and K.E.B.; data curation, R.B.H., A.M.O. and K.E.B.; writing—original draft preparation, R.B.H.;
writing—review and editing, R.B.H., A.L.J., A.M.O., B.J.L., J.M.S., R.P.M. and K.E.B.; approval of
the submitted version, R.B.H., A.L.J., A.M.O., B.J.L., J.M.S., R.P.M. and K.E.B.; supervision, R.B.H.;
project administration, R.B.H.; funding acquisition, R.B.H. All authors agree to be accountable for the
integrity of their work. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by the National Institutes of Health HL085122 (RBH) and
HL117851 (RBH), and an Institutional Clinical and Translational Science Award, NIH/NCRR
1UL1RR026314.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki and approved by the Institutional Review Boards of Cincinnati Children’s
Hospital Medical Center (protocol 2008-0892, date of approval 14 April 2008), Good Samaritan
Hospital, Cincinnati, Ohio (protocol 11027-11-016, date of approval 25 February 2011), and the
Institutional Committee on Clinical Investigations, Children’s Hospital Boston (protocol NS09-090490, date of approval 22 September 2009).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Acknowledgments: We thank Michelle Faust, Varun Krishnamurthy, and Hanna Osinska for
their assistance.
Conflicts of Interest: The authors have no disclosure to make.

References
1.
2.

3.

4.
5.

6.
7.
8.
9.
10.

Nkomo, V.T.; Gardin, J.M.; Skelton, T.N.; Gottdiener, J.S.; Scott, C.G.; Enriquez-Sarano, M. Burden of valvular heart diseases:
A population-based study. Lancet 2006, 368, 1005–1011. [CrossRef]
Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Blaha, M.J.; Dai, S.; Ford, E.S.; Fox, C.S.; Franco, S.; et al. Heart
Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association. Circulation 2013, 129, e28–e292.
[CrossRef]
Bonow, R.O.; Carabello, B.A.; Chatterjee, K.; de Leon, A.C.; Faxon, D.P.; Freed, M.D.; Gaasch, W.H.; Lytle, B.W.; Nishimura, R.A.;
O’Gara, P.T.; et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With
Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease)
Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and
Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2008, 52, e1–e142. [CrossRef]
Otto, C.M. Valvular Aortic Stenosis: Disease Severity and Timing of Intervention. J. Am. Coll. Cardiol. 2006, 47, 2141–2151.
[CrossRef]
Rajamannan, N.M.; Evans, F.J.; Aikawa, E.; Grande-Allen, K.J.; Demer, L.L.; Heistad, D.D.; Simmons, C.A.; Masters, K.S.; Mathieu, P.;
O’Brien, K.D.; et al. Calcific aortic valve disease: Not simply a degenerative process: A review and agenda for research from
the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Circulation 2011, 124, 1783–1791. [CrossRef]
[PubMed]
Schoen, F.J. Evolving concepts of cardiac valve dynamics: The continuum of development, functional structure, pathobiology,
and tissue engineering. Circulation 2008, 118, 1864–1880. [CrossRef] [PubMed]
Hinton, R.B.; Yutzey, K.E. Heart Valve Structure and Function in Development and Disease. Annu. Rev. Physiol. 2011, 73, 29–46.
[CrossRef] [PubMed]
Folkman, J. Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug Discov. 2007, 6, 273–286. [CrossRef]
Risau, W. Mechanisms of angiogenesis. Nat. Cell Biol. 1997, 386, 671–674. [CrossRef]
Hakuno, D.; Kimura, N.; Yoshioka, M.; Mukai, M.; Kimura, T.; Okada, Y.; Yozu, R.; Shukunami, C.; Hiraki, Y.; Kudo, A.; et al.
Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in
humans and rodents. J. Clin. Investig. 2010, 120, 2292–2306. [CrossRef] [PubMed]

J. Cardiovasc. Dev. Dis. 2021, 8, 75

11.

12.
13.

14.

15.
16.

17.
18.
19.

20.
21.
22.
23.
24.
25.
26.

27.
28.
29.
30.
31.
32.
33.
34.
35.

36.
37.

13 of 15

Rajamannan, N.M.; Nealis, T.B.; Subramaniam, M.; Pandya, S.; Stock, S.R.; Ignatiev, C.I.; Sebo, T.J.; Rosengart, T.K.; Edwards, W.D.;
McCarthy, P.M.; et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression
and osteoblast-like bone formation. Circulation 2005, 111, 3296–3301. [CrossRef]
Soini, Y.; Salo, T.; Satta, J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum. Pathol. 2003,
34, 756–763. [CrossRef]
Syvaranta, S.; Helske, S.; Laine, M.; Lappalainen, J.; Kupari, M.; Mayranpaa, M.I.; Lindstedt, K.A.; Kovanen, P.T. Vascular
endothelial growth factor-secreting mast cells and myofibroblasts: A novel self-perpetuating angiogenic pathway in aortic valve
stenosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1220–1227. [CrossRef] [PubMed]
Caira, F.C.; Stock, S.R.; Gleason, T.G.; McGee, E.C.; Huang, J.; Bonow, R.O.; Spelsberg, T.C.; McCarthy, P.M.; Rahimtoola, S.H.;
Rajamannan, N.M. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related
protein 5 receptor-mediated bone formation. J. Am. Coll. Cardiol. 2006, 47, 1707–1712. [CrossRef] [PubMed]
Mohler, E.R.; Gannon, F.; Reynolds, C.; Zimmerman, R.; Keane, M.G.; Kaplan, F.S. Bone Formation and Inflammation in Cardiac
Valves. Circulation 2001, 103, 1522–1528. [CrossRef] [PubMed]
Rossebø, A.B.; Pedersen, T.R.; Boman, K.; Brudi, P.; Chambers, J.B.; Egstrup, K.; Gerdts, E.; Gohlke-Bärwolf, C.; Holme, I.;
Kesäniemi, Y.A.; et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N. Engl. J. Med. 2008, 359,
1343–1356. [CrossRef] [PubMed]
Schoen, F.J. Aortic valve structure-function correlations: Role of elastic fibers no longer a stretch of the imagination. J. Hear. Valve
Dis. 1997, 6, 1–6.
Vesely, I. The role of elastin in aortic valve mechanics. J. Biomech. 1997, 31, 115–123. [CrossRef]
Fondard, O.; Detaint, D.; Iung, B.; Choqueux, C.; Adle-Biassette, H.; Jarraya, M.; Hvass, U.; Couetil, J.-P.; Henin, D.; Michel, J.-B.; et al.
Extracellular matrix remodelling in human aortic valve disease: The role of matrix metalloproteinases and their tissue inhibitors.
Eur. Heart J. 2005, 26, 1333–1341. [CrossRef]
Hinton, R.B.; Lincoln, J.; Deutsch, G.H.; Osinska, H.; Manning, P.B.; Benson, D.W.; Yutzey, K. Extracellular Matrix Remodeling
and Organization in Developing and Diseased Aortic Valves. Circ. Res. 2006, 98, 1431–1438. [CrossRef]
Wirrig, E.E.; Hinton, R.B.; Yutzey, K.E. Differential expression of cartilage and bone-related proteins in pediatric and adult
diseased aortic valves. J. Mol. Cell. Cardiol. 2011, 50, 561–569. [CrossRef] [PubMed]
Eronen, M.; Peippo, M.; Hiippala, A.; Raatikka, M.; Arvio, M.; Johansson, R.; Kähkönen, M. Cardiovascular manifestations in
75 patients with Williams syndrome. J. Med. Genet. 2002, 39, 554–558. [CrossRef] [PubMed]
Roberts, W.C.; Honig, H.S. The spectrum of cardiovascular disease in the Marfan syndrome: A clinico-morphologic study of
18 necropsy patients and comparison to 151 previously reported necropsy patients. Am. Heart J. 1982, 104, 115–135. [CrossRef]
O’Connor, W.N.; Davis, J.B.; Geissler, R.; Cottrill, C.M.; Noonan, J.A.; Todd, E.P. Supravalvular aortic stenosis. Clinical and
pathologic observations in six patients. Arch. Pathol. Lab. Med. 1985, 109, 179–185. [PubMed]
Senior, R.M.; Griffin, G.L.; Mecham, R.P. Chemotactic activity of elastin-derived peptides. J. Clin. Investig. 1980, 66, 859–862.
[CrossRef] [PubMed]
Robinet, A.; Fahem, A.; Cauchard, J.-H.; Huet, E.; Vincent, L.; Lorimier, S.; Antonicelli, F.; Soria, C.; Crepin, M.; Hornebeck, W.; et al.
Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation
of MT1-MMP. J. Cell Sci. 2005, 118, 343–356. [CrossRef]
Yacoub, M.H.; Kilner, P.J.; Birks, E.J.; Misfeld, M. The aortic outflow and root: A tale of dynamism and crosstalk. Ann. Thorac.
Surg. 1999, 68, S37–S43. [CrossRef]
Anderson, R.H. Clinical anatomy of the aortic root. Heart 2000, 84, 670–673. [CrossRef]
Gross, L.; Kugel, M.A. Topographic Anatomy and Histology of the Valves in the Human Heart*. Am. J. Pathol. 1931, 7, 445–474.7.
Wagenseil, J.E.; Mecham, R.P. New insights into elastic fiber assembly. Birth Defects Res. Part C Embryo Today Rev. 2007, 81, 229–240.
[CrossRef] [PubMed]
Kielty, C.M. Elastic fibres in health and disease. Expert Rev. Mol. Med. 2006, 8, 1–23. [CrossRef]
Tseng, H.; Grande-Allen, K. Elastic fibers in the aortic valve spongiosa: A fresh perspective on its structure and role in overall
tissue function. Acta Biomater. 2011, 7, 2101–2108. [CrossRef] [PubMed]
Cleaver, O.; Krieg, P.A. Vascular Development. In Heart Development and Regeneration; Elsevier BV: Amsterdam, The Netherlands,
2010; pp. 487–528.
Alexopoulos, A.; Bravou, V.; Peroukides, S.; Kaklamanis, L.; Varakis, J.; Alexopoulos, D.; Papadaki, H. Bone regulatory factors
NFATc1 and Osterix in human calcific aortic valves. Int. J. Cardiol. 2010, 139, 142–149. [CrossRef] [PubMed]
Roberts, W.C.; Ko, J.M. Frequency by Decades of Unicuspid, Bicuspid, and Tricuspid Aortic Valves in Adults Having Isolated
Aortic Valve Replacement for Aortic Stenosis, With or Without Associated Aortic Regurgitation. Circulation 2005, 111, 920–925.
[CrossRef] [PubMed]
Stewart, B.; Siscovick, D.; Lind, B.K.; Gardin, J.M.; Gottdiener, J.S.; Smith, V.E.; Kitzman, D.W.; Otto, C.M. Clinical Factors
Associated With Calcific Aortic Valve Disease. J. Am. Coll. Cardiol. 1997, 29, 630–634. [CrossRef]
Perrotta, I.; Russo, E.; Camastra, C.; Filice, G.; Di Mizio, G.; Colosimo, F.; Ricci, P.; Tripepi, S.; Amorosi, A.; Triumbari, F.; et al.
New evidence for a critical role of elastin in calcification of native heart valves: Immunohistochemical and ultrastructural study
with literature review. Histopathology 2011, 59, 504–513. [CrossRef]

J. Cardiovasc. Dev. Dis. 2021, 8, 75

38.

39.
40.
41.
42.
43.
44.
45.
46.
47.

48.

49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.

65.

14 of 15

Aikawa, E.; Aikawa, M.; Libby, P.; Figueiredo, J.-L.; Rusanescu, G.; Iwamoto, Y.; Fukuda, D.; Kohler, R.H.; Shi, G.-P.; Jaffer, F.A.; et al.
Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease. Circulation
2009, 119, 1785–1794. [CrossRef]
Jain, D.; Dietz, H.C.; Oswald, G.L.; Maleszewski, J.J.; Halushka, M.K. Causes and histopathology of ascending aortic disease in
children and young adults. Cardiovasc. Pathol. 2011, 20, 15–25. [CrossRef]
Holbrook, K.A.; Byers, P.H. Structural abnormalities in the dermal collagen and elastic matrix from the skin of patients with
inherited connective tissue disorders. J. Investig. Dermatol. 1982, 79, 7s–16s. [CrossRef]
Balguid, A.; Driessen, N.J.; Mol, A.; Schmitz, J.P.; Verheyen, F.; Bouten, C.V.; Baaijens, F.P. Stress related collagen ultrastructure in
human aortic valves—implications for tissue engineering. J. Biomech. 2008, 41, 2612–2617. [CrossRef]
Wynn, T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Investig. 2007, 117,
524–529. [CrossRef]
Otto, C.; Kuusisto, J.; Reichenbach, D.D.; Gown, A.M.; O’Brien, K. Characterization of the early lesion of ’degenerative’ valvular
aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90, 844–853. [CrossRef]
Mohler, E.R.; Nichols, R.; Harvey, W.P.; Sheridan, M.J.; Waller, B.F. Development and progression of aortic valve stenosis:
Atherosclerosis risk factors-a causal relationship? a clinical morphologic study. Clin. Cardiol. 1991, 14, 995–999. [CrossRef]
Doetschman, T.; Barnett, J.V.; Runyan, R.; Camenisch, T.D.; Heimark, R.L.; Granzier, H.L.; Conway, S.J.; Azhar, M. Transforming
growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res. 2011, 347, 203–223. [CrossRef] [PubMed]
Markwald, R.R.; Norris, R.A.; Moreno-Rodriguez, R.; Levine, R.A. Developmental basis of adult cardiovascular diseases: Valvular
heart diseases. Ann. N. Y. Acad. Sci. 2010, 1188, 177–183. [CrossRef] [PubMed]
Gendron, N.; Rosa, M.; Blandinieres, A.; Sottejeau, Y.; Rossi, E.; Van Belle, E.; Idelcadi, S.; Lecourt, S.; Vincentelli, A.; Cras, A.; et al.
Human Aortic Valve Interstitial Cells Display Proangiogenic Properties During Calcific Aortic Valve Disease. Arter. Thromb. Vasc.
Biol. 2020, 41, 415–429. [CrossRef] [PubMed]
Arevalos, C.A.; Berg, J.M.; Nguyen, J.M.V.; Godfrey, E.L.; Iriondo, C.; Grande-Allen, K.J.; Nguyen, J.M.V. Valve Interstitial Cells
Act in a Pericyte Manner Promoting Angiogensis and Invasion by Valve Endothelial Cells. Ann. Biomed. Eng. 2016, 44, 2707–2723.
[CrossRef] [PubMed]
Katsi, V.; Magkas, N.; Antonopoulos, A.; Trantalis, G.; Toutouzas, K.; Tousoulis, D. Aortic valve: Anatomy and structure and the
role of vasculature in the degenerative process. Acta Cardiol. 2020, 1–14. [CrossRef] [PubMed]
Antonicelli, F.; Bellon, G.; Debelle, L.; Hornebeck, W. Elastin-elastases and inflamm-aging. Curr. Top Dev. Biol. 2007, 79, 99–155.
[PubMed]
Pezet, M.; Jacob, M.-P.; Escoubet, B.; Gheduzzi, D.; Tillet, E.; Perret, P.; Huber, P.; Quaglino, D.; Vranckx, R.; Li, D.Y.; et al. Elastin
Haploinsufficiency Induces Alternative Aging Processes in the Aorta. Rejuvenation Res. 2008, 11, 97–112. [CrossRef] [PubMed]
Jacob, M.P. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological
conditions. Biomed. Pharmacother. 2003, 57, 195–202. [CrossRef]
Mariko, B.; Pezet, M.; Escoubet, B.; Bouillot, S.; Andrieu, J.-P.; Starcher, B.; Quaglino, D.; Jacob, M.-P.; Huber, P.; Ramirez, F.; et al.
Fibrillin-1 genetic deficiency leads to pathological ageing of arteries in mice. J. Pathol. 2011, 224, 33–44. [CrossRef]
Karnik, S.K.; Brooke, B.S.; Bayes-Genis, A.; Sorensen, L.; Wythe, J.D.; Schwartz, R.S.; Keating, M.T.; Li, D.Y. A critical role for
elastin signaling in vascular morphogenesis and disease. Development 2003, 130, 411–423. [CrossRef]
Sullivan, K.M.; Bissonnette, R.; Yanagisawa, H.; Hussain, S.N.; Davis, E.C. Fibulin-5 functions as an endogenous angiogenesis
inhibitor. Lab. Investig. 2007, 87, 818–827. [CrossRef]
Long, M.M.; King, V.J.; Prasad, K.U.; Freeman, B.A.; Urry, D.W. Elastin repeat peptides as chemoattractants for bovine aortic
endothelial cells. J. Cell. Physiol. 1989, 140, 512–518. [CrossRef] [PubMed]
Hollinger, J.O.; Schmitz, J.P.; Yaskovich, R.; Long, M.M.; Prasad, K.U.; Urry, D.W. A synthetic polypentapeptide of elastin for
initiating calcification. Calcif. Tissue Int. 1988, 42, 231–236. [CrossRef] [PubMed]
Cocciolone, A.J.; Johnson, E.O.; Shao, J.-Y.; Wagenseil, J.E. Elastic Fiber Fragmentation Increases Transmural Hydraulic Conductance and Solute Transport in Mouse Arteries. J. Biomech. Eng. 2018, 141, 021013. [CrossRef] [PubMed]
Thubrikar, M.J.; Aouad, J.; Nolan, S.P. Patterns of calcific deposits in operatively excised stenotic or purely regurgitant aortic
valves and their relation to mechanical stress. Am. J. Cardiol. 1986, 58, 304–308. [CrossRef]
Balachandran, K.; Sucosky, P.; Jo, H.; Yoganathan, A.P. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps:
Implications for degenerative aortic valve disease. Am. J. Physiol. Circ. Physiol. 2009, 296, H756–H764. [CrossRef] [PubMed]
Grande, K.J.; Cochran, R.P.; Reinhall, P.G.; Kunzelman, K.S. Stress Variations in the Human Aortic Root and Valve: The Role of
Anatomic Asymmetry. Ann. Biomed. Eng. 1998, 26, 534–545. [CrossRef]
Peacock, J.A. An in vitro study of the onset of turbulence in the sinus of Valsalva. Circ. Res. 1990, 67, 448–460. [CrossRef]
Woo, K.V.; Qu, X.; Babaev, V.R.; Linton, M.F.; Guzman, R.J.; Fazio, S.; Baldwin, H.S. Tie1 attenuation reduces murine atherosclerosis
in a dose-dependent and shear stress–specific manner. J. Clin. Investig. 2011, 121, 1624–1635. [CrossRef]
Hinton, R.B.; Adelman-Brown, J.; Witt, S.; Krishnamurthy, V.K.; Osinska, H.; Sakthivel, B.; James, J.F.; Li, D.Y.; Narmoneva, D.A.;
Mecham, R.P.; et al. Elastin Haploinsufficiency Results in Progressive Aortic Valve Malformation and Latent Valve Disease in a
Mouse Model. Circ. Res. 2010, 107, 549–557. [CrossRef]
Krishnamurthy, V.K.; Opoka, A.M.; Kern, C.B.; Guilak, F.; Narmoneva, D.A.; Hinton, R.B. Maladaptive matrix remodeling and
regional biomechanical dysfunction in a mouse model of aortic valve disease. Matrix Biol. 2012, 31, 197–205. [CrossRef]

J. Cardiovasc. Dev. Dis. 2021, 8, 75

66.
67.
68.

69.

70.

71.

72.

73.

74.
75.

15 of 15

Votteler, M.; Berrio, D.A.; Horke, A.; Sabatier, L.; Reinhardt, D.P.; Nsair, A.; Aikawa, E.; Schenke-Layland, K. Elastogenesis at the
onset of human cardiac valve development. Development 2013, 140, 2345–2353. [CrossRef]
Munjal, C.; Opoka, A.; Osinska, H.; James, J.F.; Bressan, G.M.; Hinton, R.B. TGF-Beta Mediates Early Angiogenesis and Latent
Fibrosis in an Emilin1-Deficient Model of Aortic Valve Disease. Dis. Models Mech. 2014, 7, 987–996. [CrossRef]
Hanada, K.; Vermeij, M.; Garinis, G.A.; De Waard, M.C.; Kunen, M.G.; Myers, L.; Maas, A.; Duncker, D.J.; Meijers, C.; Dietz, H.C.; et al.
Perturbations of Vascular Homeostasis and Aortic Valve Abnormalities in Fibulin-4 Deficient Mice. Circ. Res. 2007, 100, 738–746.
[CrossRef] [PubMed]
Ng, C.M.; Cheng, A.; Myers, L.A.; Martinez-Murillo, F.; Jie, C.; Bedja, D.; Gabrielson, K.L.; Hausladen, J.M.W.; Mecham, R.P.;
Judge, D.P.; et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J. Clin.
Investig. 2004, 114, 1586–1592. [CrossRef]
Dor, Y.; Camenisch, T.D.; Itin, A.; Fishman, G.I.; McDonald, J.A.; Carmeliet, P.; Keshet, E. A novel role for VEGF in endocardial
cushion formation and its potential contribution to congenital heart defects. Development 2001, 128, 1531–1538. [CrossRef]
[PubMed]
Snider, P.; Hinton, R.B.; Moreno-Rodriguez, R.A.; Wang, J.; Rogers, R.; Lindsley, A.; Li, F.; Ingram, D.A.; Menick, D.; Field, L.; et al.
Periostin Is Required for Maturation and Extracellular Matrix Stabilization of Noncardiomyocyte Lineages of the Heart. Circ. Res.
2008, 102, 752–760. [CrossRef] [PubMed]
Yoshioka, M.; Yuasa, S.; Matsumura, K.; Kimura, K.; Shiomi, T.; Kimura, N.; Shukunami, C.; Okada, Y.; Mukai, M.; Shin, H.; et al.
Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat. Med. 2006, 12, 1151–1159. [CrossRef]
[PubMed]
Barolet, A.W.; Nili, N.; Cheema, A.; Robinson, R.; Natarajan, M.K.; O’Blenes, S.; Li, J.; Eskandarian, M.R.; Sparkes, J.; Rabinovitch, M.; et al.
Arterial Elastase Activity After Balloon Angioplasty and Effects of Elafin, an Elastase Inhibitor. Arter. Thromb. Vasc. Biol. 2001, 21,
1269–1274. [CrossRef] [PubMed]
Otto, C.; Lind, B.K.; Kitzman, D.W.; Gersh, B.J.; Siscovick, D.S. Association of Aortic-Valve Sclerosis with Cardiovascular Mortality
and Morbidity in the Elderly. N. Engl. J. Med. 1999, 341, 142–147. [CrossRef] [PubMed]
Schoen, F.J. Mechanisms of Function and Disease of Natural and Replacement Heart Valves. Annu. Rev. Pathol. Mech. Dis. 2012, 7,
161–183. [CrossRef]

